Investment Considerations InMed is a global leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs. The company in April 2024 announced preclinical data for its INM-089 drug candidate, further demonstrating positive pharmacological effects targeting dry AMD. InMed that same month announced preclinical data demonstrating its INM-901 drug candidate’s positive … Continue reading “InMed Pharmaceuticals Inc. (NASDAQ: INM)”
Symbol | Release | Time |
---|---|---|
{{ release.qmtopics.qmsymbol[0].symbol }} | {{ release.headline }} | {{ release.datetime | amDateFormat:'hh:mm A'}} |